149 related articles for article (PubMed ID: 11285791)
1. BCG immunotherapy for superficial bladder cancer.
Lockyer CR; Gillatt DA
J R Soc Med; 2001 Mar; 94(3):119-23. PubMed ID: 11285791
[No Abstract] [Full Text] [Related]
2. Experience with intravesical bacillus Calmette-Guèrin therapy of superficial bladder tumors.
Herr HW; Pinsky CM; Whitmore WF; Sogani PG; Oettgen HF; Melamed MR
Urology; 1985 Feb; 25(2):119-23. PubMed ID: 3881870
[TBL] [Abstract][Full Text] [Related]
3. Bacillus Calmette-Guérin and superficial bladder cancer. Clinical experience and mechanism of action.
Catalona WJ; Ratliff TL
Surg Annu; 1990; 22():363-78. PubMed ID: 2408170
[No Abstract] [Full Text] [Related]
4. BCG-RIVM versus BCG-Tice versus mitomycin-C in superficial bladder cancer. Rationale and design of the trial of the Southeast Co-operative Urological Group, The Netherlands.
van der Meijden PM; Debruyne FM; Steerenberg PA; de Jong WH; Doesburg W
Prog Clin Biol Res; 1989; 310():285-98. PubMed ID: 2505272
[No Abstract] [Full Text] [Related]
5. [Treatment of superficial tumors of the bladder with bacillus Calmette-Guérin].
Ackermann D; Schnyder M; Bandelier D; Studer UE
J Urol (Paris); 1986; 92(1):33-8. PubMed ID: 3722851
[TBL] [Abstract][Full Text] [Related]
6. Multicenter study of the BCG Tokyo strain for intravesical treatment in patients with superficial bladder cancer. BCG Study Group.
Aso Y; Akaza H; Kameyama S; Niijima T
Prog Clin Biol Res; 1989; 303():383-91. PubMed ID: 2675000
[No Abstract] [Full Text] [Related]
7. Clinical evaluation of immunotherapy: are there differences between papillary and flat in situ bladder cancer?
Lamm DL
Cancer Surv; 1998; 31():99-108. PubMed ID: 15281319
[TBL] [Abstract][Full Text] [Related]
8. Results of a Randomised Controlled Trial Comparing Intravesical Chemohyperthermia with Mitomycin C Versus Bacillus Calmette-Guérin for Adjuvant Treatment of Patients with Intermediate- and High-risk Non-Muscle-invasive Bladder Cancer.
Arends TJ; Nativ O; Maffezzini M; de Cobelli O; Canepa G; Verweij F; Moskovitz B; van der Heijden AG; Witjes JA
Eur Urol; 2016 Jun; 69(6):1046-52. PubMed ID: 26803476
[TBL] [Abstract][Full Text] [Related]
9. Possible factors affecting response to intravesical bacillus Calmette-Guérin (Tokyo 172 strain) therapy for carcinoma in situ of the bladder: a multivariate analysis.
Takashi M; Katsuno S; Yuba H; Ohshima S; Wakai K; Ohno Y
Int Urol Nephrol; 1998; 30(6):713-22. PubMed ID: 10195866
[TBL] [Abstract][Full Text] [Related]
10. Retrospective study of efficacy of intravesical BCG alone in treatment of superficial bladder cancer.
Mydlo JH; Usher SM; Camacho F; Freed S
Urology; 1986 Sep; 28(3):173-5. PubMed ID: 3750596
[TBL] [Abstract][Full Text] [Related]
11. BCG-RIVM intravesical immunoprophylaxis for superficial bladder cancer.
Debruyne FM; van der Meijden AP; Schreinemachers LM; Geboers AD; Franssen MP; van Leeuwen MJ; Steerenberg PA; de Jong WH; Ruitenberg EJ
Prog Clin Biol Res; 1988; 269():511-24. PubMed ID: 3134662
[No Abstract] [Full Text] [Related]
12. Bacillus Calmette-Guérin treatment of existing papillary bladder cancer and carcinoma in situ of the bladder. Four-year results. The Bladder Cancer BCG Study Group.
Akaza H; Hinotsu S; Aso Y; Kakizoe T; Koiso K
Cancer; 1995 Jan; 75(2):552-9. PubMed ID: 7812924
[TBL] [Abstract][Full Text] [Related]
13. [BCG immunotherapy in the treatment of superficial bladder tumors].
Samodai L; Drinóczy M; Kolozsy Z; Mohácsi L; Dauda G; Porkoláb Z
Orv Hetil; 1986 Oct; 127(40):2441-6. PubMed ID: 3537907
[No Abstract] [Full Text] [Related]
14. BCG-RIVM versus BCG-Tice versus mitomycin-C in superficial bladder cancer. Rationale, design, and interim analysis of the trial of the South-East Cooperative Urological Group, The Netherlands.
Witjes WP; van der Meijden PM; Roos EP; Witjes JA; Steerenberg PA; Doesburg W; Debruyne FM
Prog Clin Biol Res; 1992; 378():59-67. PubMed ID: 1301587
[No Abstract] [Full Text] [Related]
15. Superficial bladder disease: case studies and therapeutic advances.
Soloway MS; Droller MJ; Flanigan RC; Nseyo UO
Urology; 1992 Dec; 40(6 Suppl):11-22. PubMed ID: 1466118
[No Abstract] [Full Text] [Related]
16. Intravesical Bacillus Calmette Guerin therapy in patients with superficial bladder tumor.
Steg A; Belas M; Leleu C; Boccon-Gibod L
Prog Clin Biol Res; 1989; 303():375-81. PubMed ID: 2780654
[No Abstract] [Full Text] [Related]
17. [Immunotherapy in superficial bladder carcinoma].
Ríos González E; Martínez-Piñeiro Lorenzo L; Martínez-Piñeiro Caramés JA; de la Peña Barthel JJ
Arch Esp Urol; 2000 Dec; 53(10):879-92. PubMed ID: 11213392
[TBL] [Abstract][Full Text] [Related]
18. BCG treatment of existing Ta, T1 tumours or carcinoma in situ of the bladder.
Akaza H
Eur Urol; 1995; 27 Suppl 1():9-12. PubMed ID: 7750530
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of clinical data in bladder cancer immunotherapy with Connaught BCG (ImmuCyst).
Barreto L; Csizer Z; Sparkes JD
Dev Biol Stand; 1992; 77():229-31. PubMed ID: 1426667
[TBL] [Abstract][Full Text] [Related]
20. Mitomycin-C and BCG in intravesical chemotherapy and immunotherapy of superficial bladder cancer. Finnbladder Research Group.
Rintala E; Jauhiainen K; Alfthan O
Prog Clin Biol Res; 1989; 310():271-4. PubMed ID: 2505270
[No Abstract] [Full Text] [Related]
[Next] [New Search]
